YS Biopharma Co., Ltd. (YS)
NASDAQ: YS · IEX Real-Time Price · USD
0.722
+0.012 (1.63%)
At close: Mar 28, 2024, 1:20 PM
0.706
-0.016 (-2.23%)
After-hours: Mar 28, 2024, 6:08 PM EDT

YS Biopharma Co. Income Statement

Millions CNY. Fiscal year is Apr - Mar.
Year 202220212020
Revenue
687.2502.95257.02
Revenue Growth (YoY)
36.63%95.69%-
Cost of Revenue
153.36117.0759.66
Gross Profit
533.84385.88197.36
Selling, General & Admin
354.52293.62228.82
Research & Development
318.7211.2294.39
Operating Expenses
673.22504.84323.21
Operating Income
-139.38-118.96-125.85
Interest Expense / Income
30.862.7229.69
Other Expense / Income
112.1110.0535.44
Pretax Income
-282.34-231.73-190.98
Income Tax
1.134.9417.45
Net Income
-283.47-236.67-208.44
Preferred Dividends
137.99130.6616.61
Net Income Common
-421.46-367.33-225.05
Shares Outstanding (Basic)
936262
Shares Outstanding (Diluted)
936262
Shares Change
50.51%--
EPS (Basic)
-1.56-1.71-3.10
EPS (Diluted)
-1.56-1.71-3.10
Free Cash Flow
-235.16-468.85-350.85
Free Cash Flow Per Share
-2.53-7.58-5.67
Gross Margin
77.68%76.72%76.79%
Operating Margin
-20.28%-23.65%-48.96%
Profit Margin
-61.33%-73.03%-87.56%
Free Cash Flow Margin
-34.22%-93.22%-136.51%
EBITDA
-210.37-194.07-131.15
EBITDA Margin
-30.61%-38.59%-51.03%
Depreciation & Amortization
41.1134.9430.14
EBIT
-251.48-229.01-161.29
EBIT Margin
-36.59%-45.53%-62.76%
Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).